Abstracts Archive - Page 289 of 2607 - ACR Meeting Abstracts

Abstract Number: 1531 • ACR Convergence 2024
Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Meggan Mackay¹, Catriona Wagner², Ashley Pinckney³, Jeffrey Cohen⁴, Zachary Wallace⁵, Arezou Khosroshahi⁶, Jeffrey Sparks⁷, Sandra Lord⁸, Amit Saxena⁹, Roberto Caricchio¹⁰, Alfred Kim¹¹, Diane Kamen¹², Fotios Koumpouras¹³, Anca Askanase¹⁴, Kenneth Smith¹⁵, Joel Guthridge¹⁵, Susan Macwana¹⁶, Sean McCarthy¹⁷, Matthew Sherman¹⁸, Sanaz Daneshfar Hamrah¹⁹, Maria Veri¹⁹, Kate York²⁰, Sarah Walker²¹, Sandeep Narpala²², Robin Carroll²², Bob Lin²², Leonid Serebryanny²², Adrian McDermott²³, William Barry²¹, Ellen Goldmuntz²⁴, James McNamara²⁵, Sara Tedeschi²⁶, Amit Bar-Or²⁷, Dinesh Khanna²⁸, ACV01 Clinical Study Team¹⁵ and Judith James¹⁵, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Rho, St Louis Park, NC, ⁴Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH, ⁵Massachusetts General Hospital, Newton, MA, ⁶Emory University, Atlanta, GA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁸Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA., Seattle, WA, ⁹NYU School of Medicine, New York, NY, ¹⁰University of Massachusetts Chan Medical School, Worcester, MA, ¹¹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹²Medical University of South Carolina, Charleston, SC, ¹³Yale School of Medicine, New Haven, CT, ¹⁴Columbia University Medical Center, New York, NY, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Oklahoma Medical Research Foundation, Oklahoma City, ¹⁷DAIT/NIAID/NIH, Rockville, MD, ¹⁸DAIT/NIAID/NIH, Washington, DC, ¹⁹Division of Allergy, Immunology, and Transplantation, NIH/NIAID, Bethesda, MD, USA., Bethesda, MD, ²⁰Rho Federal Systems Division, Durham, NC, USA., Durham, NC, ²¹Rho, Durham, NC, ²²Vaccine Research Center, NIH/NIAID, Bethesda, MD, USA, Bethesda, MD, ²³Vaccine Research Center, NIH/NIAID, Bethesda, MD, ²⁴NIAID/ NIH, Washington, DC, ²⁵NIH, Bethesda, MD, ²⁶Brigham and Women's Hospital, Boston, MA, ²⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, Philadelphia, PA, ²⁸Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Autoimmune disease patients treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), or B cell-depleting therapies (BCDT) exhibit reduced humoral responses following primary two-dose COVID-19…
Abstract Number: 1514 • ACR Convergence 2024
Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Erik Cimé-Aké¹, Guadalupe Lima², Emilio G. Lazarini¹, Sandra Juárez³, Luis Llorente² and Hilda Fragoso-Loyo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Neurology and Psychiatry Department, Mexico City, Mexico
Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) may result from a chronic pro-inflammatory state in which immunosenescent and exhausted T-lymphocytes could be involved.…
Abstract Number: 1527 • ACR Convergence 2024
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…
Abstract Number: 0377 • ACR Convergence 2024
Improving Self-Management Support in Patients with Juvenile Idiopathic Arthritis
Julia Harris¹, Leslie Favier², Emily Fox³, Michael Holland³, Cara Hoffart⁴, Maria Ibarra³, Jordan Jones⁴, Susan Parish², Kara Remick-Erickson² and Ashley Cooper⁴, ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, ³Children's Mercy Hospital, Kansas City, MO, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Self-management support (SMS) is one of the key elements of the Chronic Care Model as it is an important aspect of the care for…
Abstract Number: 1019 • ACR Convergence 2024
The Impact of Race and Ethnicity and Historical Redlining on Psoriatic Disease Burden
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Previous literature has suggested racial and ethnic variations in the clinical expression of psoriatic disease, with Non-White patients having more extensive skin disease, higher…
Abstract Number: 1278 • ACR Convergence 2024
The Effects of Fatigue on Self-Reported Mental and Physical Health in Childhood-Onset Systemic Lupus Erythematosus: A Cross-Sectional Study
Hunter Hogarth¹, Jida Jaffan¹, Tala El Tal², Oscar Mwizerwa¹, Asha Jeyanathan¹, Ibrahim Mohamed³, Lawrence Ng⁴, Paris Moaf⁵, Joanna Law⁵, Louise Boulard⁶, Ashley Danguecan⁷, Adrienne Davis⁸, Linda Hiraki⁴, Deborah Levy⁴ and Andrea Knight⁹, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ²The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Neurosciences and Mental Health Program, SickKids Research Institute; The Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ⁸Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Fatigue is a prevalent and distressing symptom in childhood-onset systemic lupus erythematosus (cSLE), affecting up to 74% of patients with potential for adverse effects…
Abstract Number: 1542 • ACR Convergence 2024
Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
Arezou Khosroshahi¹, Sarah Welsh², Liangwei Wang², David Larson² and Nisha Jain², ¹Emory University, Atlanta, GA, ²Amgen, Inc., Rockville, MD
Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…
Abstract Number: 1490 • ACR Convergence 2024
Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Vasileios Kyttaris¹, Andrew Concoff², Touba Warsi³, Sepehr Taghavi³, Sudha Kumar³, Stanley Park³, Abigail Patalinghug³, Christine Schleif³, Brittany Partain⁴, Joseph Ahearn⁵, Nicole Wilson⁶, Chau-Ching Liu⁶, Susan Manzi⁶ and Tyler O'Malley⁷, ¹BIDMC, Boston, MA, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Allegheny Health Network, Wexford, PA, ⁶Allegheny Health Network, Pittsburgh, PA, ⁷Exagen, Vista, CA
Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
Abstract Number: 1523 • ACR Convergence 2024
Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020
Husam El Sharu, East Carolina University, Greenville, NC
Background/Purpose: Introduction: In the past decade, the incidence of Lupus Nephritis (LN) flares linked to mortality has generally decreased, though an upward trend has emerged…
Abstract Number: 1538 • ACR Convergence 2024
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Meenakshi Jolly¹, Matt Truman², Ronald Flauto³ and Kathryn Dao⁴, ¹Rush University, Chicago, IL, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals, Rockville, MD, ⁴Rheum101, Rockville, MD
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
Abstract Number: 1502 • ACR Convergence 2024
The Systemic Lupus International Collaborating Clinics (SLICC) Frailty Index (SLICC-FI) Predicts Hospitalizations. Data from the Almenara Lupus Cohort
Manuel Ugarte-Gil¹, RV, Gamboa-Cardenas², Victor Pimentel-Quiroz³, Cristina Reategui⁴, Claudia Elera Fitzcarrald⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela Alarcon⁷, ¹Universidad Cientifica del Sur, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Lima, Peru, ³Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ⁴Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen/Universidad San Ignacio de Loyola, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Frailty, measured with the SLICC-FI, has been reported as a predictor of damage in several cohorts. The aim of this study is to evaluate…
Abstract Number: 1406 • ACR Convergence 2024
Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease
Negaar Goudarzi¹, Loïc Meudec², Juliette Pascaud², Fanny Jaulin³, Quentin Pascal⁴, Thierry Lazure⁵, Sacha E Silva Saffar², Xavier Mariette⁶ and Gaetane Nocturne⁶, ¹University Paris-Saclay, Le Kremlin Bicêtre, France, ²University Paris Saclay, Le Kremlin Bicetre, France, ³Institut Gustave Roussy, Villejuif, France, ⁴CEA, Fontenay aux roses, France, ⁵APHP. Université Paris-Saclay, Hôpital Bicêtre, Anatomie et cytologie pathologiques, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease that manifests as glandular dryness and systemic symptoms. Salivary gland epithelial cells (SGEC) are pivotal in…
Abstract Number: 1534 • ACR Convergence 2024
Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications
April Jorge¹, Kila Panchot², Baijun Zhou², Aakash Patel¹ and Hyon K. Choi³, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have nephroprotective and cardioprotective benefits and may have a role in lupus nephritis (LN) treatment. 2023 EULAR SLE treatment guidelines…
Abstract Number: 1536 • ACR Convergence 2024
Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
JM JANSZ¹, EA Troy², WL Galanter³, Elaine Adams⁴, Nadera Sweiss⁵ and HJ CHANG⁶, ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois at Chicago, Woodridge, IL, ³University of Illinois at Chicago; Jesse Brown VA Medical Center, CHICAGO, IL, ⁴Jesse Brown VA Medical Center, La Grange, IL, ⁵University of IL, Chicago, IL, ⁶RHEUMATOLOGIST, CHICAGO, IL
Background/Purpose: Lupus nephritis is a well-known and severe complication in patients with systemic lupus erythematosus (SLE) that can lead to significant morbidity and mortality. Angiotensin-converting…
Abstract Number: 1504 • ACR Convergence 2024
Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6
Emma Neary¹, Carolina Munoz-Grajales², Joan Wither³, Juan Pablo Diaz Martinez³, Michelle Barraclough⁴, Kathleen Bingham³, Roberta Kretzmann³, Maria Carmela Tartaglia⁵, Lesley Ruttan⁶, May Choi⁷, Simone Appenzeller⁸, Sherief Marzouk³, Dennisse Bonilla³, Patti Katz⁹, Dorcas Beaton¹⁰, Robin Green³, Laura Patricia Whittall Garcia³, Dafna Gladman¹¹ and Zahi Touma¹², ¹McGill University, Montreal, QC, Canada, ²UHN/TWH, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The University of Manchester, Manchester, United Kingdom, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Toronto Rehab/University Health Network - University Centre, Toronto, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, SP, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada

Background/Purpose: Cognitive impairment (CI) is an increasingly prevalent neuropsychiatric manifestation in patients with systemic lupus erythematosus (SLE). Although CI has been identified through patient-reported outcomes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].